Vaccinex, Inc. Stock News
$0.70
45.52%
yesterday
Nasdaq,
Nov 14, 09:58 pm CET
Vaccinex, Inc. Stock News
Neutral
GlobeNewsWire
●
6 months ago
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
